Opinion|Videos|October 29, 2024
Barriers to VMS Treatment and Impact on Long-Term Health
Key Takeaways
- Misconceptions about menopause and lack of awareness among healthcare providers contribute to under-treatment of VMS in menopausal women.
- Patient resistance to HRT and nonhormonal treatments like SSRIs and gabapentin is driven by concerns about side effects and long-term risks.
Panelists discuss how underlying factors, including patient resistance to conventional treatments and the stigma surrounding menopause, contribute to the persistent undertreatment of vasomotor symptoms (VMS), which can severely impact women’s quality of life and increase their risk for long-term health issues such as cardiovascular disease and Alzheimer disease.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What underlying factors do you think contribute to the persistent under-treatment of VMS in menopausal women, despite the high prevalence of these symptoms?
- What factors contribute to patient resistance to conventional VMS treatment options, specifically hormone replacement therapies and nonhormonal therapies such as SSRIs [selective serotonin reuptake inhibitors] and gabapentin?
- How do untreated VMS impact the overall quality of life and long-term health outcomes for women, such as risk for cardiovascular disease and Alzheimer’s disease?
Advertisement
Related to this article
Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
In more than 250,000 adults with prediabetes and obesity, GLP-1 users had lower risks of type 2 diabetes, death, and cardiovascular events.
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
In nearly 443,000 US adults, both low-frequency and heavy cannabis use were linked to higher odds of cardiovascular disease, led by stroke.
Clinicians separate idiopathic hypersomnia from depression-related sleepiness and interpret real-world and trial data for better outcomes.
Erythema-based criteria miss skin of color, urging ROSCO phenotyping to improve diagnostic equity in dermatology.
New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.
Advertisement
Advertisement
Trending on AJMC
1
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
2
Enlicitide LDL-C Lowering Holds Across Risk Levels Up to 2 Years
3
FDA Approves First Plasmid DNA-Based Immunotherapy for Adults With RRP
4
Tegoprubart Eases Symptom Burden vs Tacrolimus After Kidney Transplant
5